Pharming Technologies B.V.

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Leniolisib for Immune Dysregulation in PIDs

Phase 2

Recruiting

Conditions: Primary Immunodeficiency Disorders (PIDs)

Interventions: Drug: Leniolisib

First Posted Date: 2024-08-12

Last Posted Date: 2024-11-12

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 12

Registration Number: NCT06549114

Locations: 🇺🇸
National Institute of Health, Bethesda, Maryland, United States

An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

Phase 3

Recruiting

Conditions: APDS Gene Mutation

Interventions: Drug: Leniolisib

First Posted Date: 2024-02-08

Last Posted Date: 2024-02-08

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 3

Registration Number: NCT06249997

Locations: 🇯🇵
Hiroshima University Hospital, Hiroshima, Hiroshima City, Japan
🇯🇵
Tokyo Medical And Dental University Hospital, Tokyo, Bunkyo-ku, Japan

Pediatric Patients Aged 1 to 6 Years with APDS

Phase 3

Recruiting

Conditions: APDS

Interventions: Drug: Leniolisib

First Posted Date: 2023-01-20

Last Posted Date: 2024-12-17

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 15

Registration Number: NCT05693129

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
National Institutes of Health, Bethesda, Maryland, United States
🇺🇸
The University of North Carolina, Chapel Hill, North Carolina, United States

and more 7 locations

Pediatric Patients Aged 4 to 11 Years With APDS

Phase 3

Active, not recruiting

Conditions: APDS

Interventions: Drug: Leniolisib

First Posted Date: 2022-06-30

Last Posted Date: 2024-07-23

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 15

Registration Number: NCT05438407

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇫🇷
Necker Hospital Paris, Paris, France

and more 4 locations

Prevention of Acute Kidney Injury in Patients With NSTEMI

Phase 2

Terminated

Conditions: Non-ST Elevation Myocardial Infarction (NSTEMI)

Interventions: Drug: conestat alfa or placebo

First Posted Date: 2021-06-03

Last Posted Date: 2024-04-03

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 29

Registration Number: NCT04912141

Locations: 🇨🇭
Fondazione Istituto Cardiocentro Ticino, Lugano, Switzerland
🇨🇭
University Hospital Geneva, Geneva, Switzerland
🇨🇭
University Hospital Basel, Basel, Switzerland

and more 1 locations

Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Phase 2

Completed

Conditions: Confirmed Coronavirus Disease

Interventions: Drug: Ruconest

First Posted Date: 2020-08-28

Last Posted Date: 2024-02-16

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 38

Registration Number: NCT04530136

Locations: 🇺🇸
Virtua Marlton Hospital, Marlton, New Jersey, United States
🇺🇸
Virtua Voorhees Hospital, Voorhees, New Jersey, United States
🇺🇸
Virtua Memorial Hospital, Mount Holly, New Jersey, United States

and more 1 locations

Patient Registry to Evaluate the Real-world Safety of Ruconest®

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: rhC1INH

First Posted Date: 2018-10-05

Last Posted Date: 2024-04-05

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 152

Registration Number: NCT03697187

Locations: 🇺🇸
The US Hereditary Angioedema Association, Fairfax, Virginia, United States

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

Phase 2

Active, not recruiting

Conditions: Activated PI3Kdelta Syndrome (APDS); PASLI Disease

Interventions: Drug: CDZ173

First Posted Date: 2016-08-09

Last Posted Date: 2024-03-22

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 37

Registration Number: NCT02859727

Locations: 🇷🇺
Pharming Investigative Site, Moscow, Russian Federation

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

Phase 2

Completed

Conditions: Hereditary Angioedema

Interventions: Biological: Recombinant human C1 inhibitor
Other: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2017-12-08

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 32

Registration Number: NCT02247739

Locations: 🇺🇸
Washington University Division of Allergy and Immunology, Saint Louis, Missouri, United States
🇨🇿
Faculty Hospital by St. Anna Brno, Department of clinical Immunology and Allergology, Brno, Czechia
🇲🇰
PHI University Clinic of Dermatology, Skopje, Macedonia, The Former Yugoslav Republic of

and more 7 locations

C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Recruiting

Conditions: Hereditary Angioedema

Interventions: Drug: rhC1INH or pdC1INH

First Posted Date: 2011-07-20

Last Posted Date: 2024-02-07

Lead Sponsor: Pharming Technologies B.V.

Target Recruit Count: 300

Registration Number: NCT01397864

Locations: 🇲🇰
PHI University Clinic of Dermatology, Skopje, North Macedonia
🇸🇮
University Clinic Golnik, Golnik, Slovenia
🇫🇷
Hospital A Michallon, CHU Grenoble, La Tronche, France

and more 14 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy